Effectiveness of monovalent 2009 pandemic influenza a virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1262-1269

  Bateman, Allen C ^a,c   Kieke, Burney A ^a   Irving, Stephanie A ^a,d,e   Meece, Jennifer K ^a   Shay, David K ^b   Belongia, Edward A ^a  

^a MARSHFIELD CLINIC   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e International Conference on Emerging Infectious Diseases   (United States)

Author keywords

case control studies; effectiveness; epidemiology; influenza; vaccine

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEASONAL INFLUENZA; UNITED STATES;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; SEASONS; WISCONSIN; YOUNG ADULT;

EID: 84875634114     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit020     Document Type: Article

References (33)

1. World Health Organization. World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic- phase6-20090611/en/index.html. Accessed 14 August 2012.
2. Centers for Disease Control and Prevention. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage- United States, October 2009-January 2010. MMWR Morb Mortal Wkly Rep 2010; 59:363-8.
3. World Health Organization. H1N1 in post-pandemic period. http:// www.who.int/mediacentre/news/statements/2010/h1n1-vpc-20100810/ en/index.html. Accessed 14 August 2012.
4. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62.
5. Centers for Disease Control and Prevention. Update: influenza activity- United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 2011; 60:705-12.
6. Barr IG, Cui L, Komadina N, et al. A new pandemic influenza A (H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill 2010; 15:19692.
7. Mak GC, Leung CK, Cheng KC, Wong KY, Lim W. Evolution of the haemagglutinin gene of the influenza A(H1N1)2009 virus isolated in Hong Kong, 2009-2011. Euro Surveill 2011; 16:19807.
8. Recommended composition of influenza vaccines for use in the 2012 southern hemisphere influenza season. Wkly Epidemiol Rec 2011; 86:457-68.
9. Pebody R, Hardelid P, Fleming D, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: Mid-season analysis 2010/ 11. Euro Surveill 2011; 16:19791.
10. Savulescu C, Jimenez-Jorge S, de Mateo S, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill 2011; 16:19820.
11. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine 2011; 29:6558-63.
12. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199: 159-67.
13. Greenlee RT. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res 2003; 1:273-80.
14. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Use of influenza A (H1N1) 2009 monovalent vaccine: Recommendations of the advisory committee on immunization practices, 2009. MMWR Recomm Rep 2009; 58:1-8.
15. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27:6546-9.
16. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1128-32.
17. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US oral neuraminidase study group. JAMA 2000; 283:1016-24.
18. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22:1189-92.
19. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002; 21:2409-19.
20. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 2011; 17:1181-7.
21. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of nonadjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6:e23085.
22. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine. Clin Infect Dis 2012; 55:951-9.
23. Ohmit SE, Petrie JG, Cross RT, et al. Influenza hemagglutinationinhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85.
24. Song JY, Cheong HJ, Seo YB, et al. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clin Vaccine Immunol 2012; 19:638-41.
25. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35.
26. Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune responsein adultsaftervaccinationwithanH1N12009pandemicinfluenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-44.
27. Wagar LE, Rosella L, Crowcroft N, et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: Implications for vaccination. PLoS One 2011; 6:e28063.
28. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37-46.
29. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406-16.
30. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and metaanalysis. Lancet Infect Dis 2012; 12:36-44.
31. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308-18.
32. Keitel WA, Cate TR, Nino D, et al. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis 2001; 183:329-32.
33. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: Effect of end points used and characteristics of vaccine failures. J Infect Dis 2011; 203:1309-15.